Anti-estrogen and Aromatase Inhibitor Response Markers
Anti-estrogen sensitivity: ER
Schwartz PE, Keating G, MacLusky N, Naftolin F, Eisenfeld A (1982) Tamoxifen therapy for advanced ovarian cancer. Obstetricia et Gynecologica 59: 583�588.
Hatch, K.D., Beecham, J.B., Blessing, J.A., and Creasman, W.T. (1991). Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68: 269-271.
Argenta, P.A., R. Ghebre, et. al. (2009). "A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer." Gynecologic Oncology. 113: 205-209
Aromatase Inhibitor sensitivity: ER
Bowman, A., Gabra, H., Langdon, S.P., Lessells, A., Stewart, M., Young, A., and Smyth, J.F. (2002). CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8: 2233-2239.
del Carmen, M.G., Fuller, A.F., Matulonis, U., Horick, N.K., Goodman, A., Duska, L.R., Penson, R., Campos, S., Roche, M., and Seiden, M.V. (2003). Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 91: 596-602.
Smyth, J. F., C. Gourley, et al. (2007). Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-22.
Ramirez, P.T., Schmeler, K.M., Milam, M.R., Slomovitz, B.M., Smith, J.A., Kavanagh, J.J., Deavers, M., Levenback, C., Coleman, R.L., and Gershenson, D.M. (2008). Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 110: 56-59.
Aromatase Inhibitor sensitivity: PR
Bowman, A., Gabra, H., Langdon, S.P., Lessells, A., Stewart, M., Young, A., and Smyth, J.F. (2002). CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8: 2233-2239.
Progestin Response Markers
Progestin sensitivity: ER
Freedman RS, Saul PB, Edwards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN, Dana WJ (1986) Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treatment Reports 70: 369-373.
Fromm, G-L., W. Scott, et al. (1991). Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer 68: 1885-89.
Progestin sensitivity: PR
Niwa, K., Onogi, K., Wu, Y., Mori, H., Harrigan, R.C., and Tamaya, T. (2008). Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study. Eur J Gynaecol Oncol 29: 252-255.